Last reviewed · How we verify

HRS-7535 Tablets — Competitive Intelligence Brief

HRS-7535 Tablets (HRS-7535 Tablets) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

phase 3 Small molecule Live · refreshed every 30 min

Target snapshot

HRS-7535 Tablets (HRS-7535 Tablets) — Shandong Suncadia Medicine Co., Ltd.. HRS-7535 is an investigational small molecule with unknown mechanism of action in Phase 3 development.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HRS-7535 Tablets TARGET HRS-7535 Tablets Shandong Suncadia Medicine Co., Ltd. phase 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HRS-7535 Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/hrs-7535-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing